Vladimir Coric
Chief Executive Officer en BIOHAVEN LTD. .
Fortuna: 172 M $ al 31/03/2024
Perfil
El Dr. Vlad Coric, MD, es director ejecutivo y director de Biohaven Pharmaceutical Holding Co. Ltd. y profesor clínico asociado de la Facultad de Medicina de Yale. Forma parte del Consejo de Administración de Biohaven Pharmaceutical Holding Co. Ltd., Our Lady of Mercy Academy, Pyramid Biosciences, Inc. y Vita Therapeutics, Inc. El Dr. Coric trabajó anteriormente como Director de Grupo-Investigación Clínica Global en Bristol Myers Squibb Co. y como Presidente de la Sociedad Psiquiátrica de Connecticut. Se doctoró en la Facultad de Medicina de Wake Forest.
Participaciones conocidas en empresas públicas
Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
---|---|---|---|---|
BIOHAVEN LTD.
3.85% | 22/04/2024 | 3 146 085 ( 3.85% ) | 172 M $ | 31/03/2024 |
08/03/2024 | 5 784 ( 0.01% ) | 28 457 $ | 31/03/2024 |
Cargos activos de Vladimir Coric
Empresas | Cargo | Inicio |
---|---|---|
BIOHAVEN LTD. | Chief Executive Officer | 02/05/2022 |
REVANCE THERAPEUTICS, INC. | Director/Board Member | 01/03/2023 |
Yale School of Medicine | Corporate Officer/Principal | 01/07/2001 |
Vita Therapeutics, Inc.
Vita Therapeutics, Inc. BiotechnologyHealth Technology Vita Therapeutics, Inc. is a biotechnology company based in Baltimore, MD that develops state-of-the-art cellular therapeutics for the treatment of neuromuscular diseases and cancers. The company uses induced pluripotent stem cell (iPSC) technology to engineer specific cell types designed to replace those that are defective in patients. Vita Therapeutics is progressing its co-leading programs VTA-100 and VTA-300 for the treatment of limb-girdle muscular dystrophy (LGMD) and multiple solid tumors with the goal of filing investigational drug applications with the Food and Drug Administration in 2023. The company is developing these proprietary cellular therapies following a dual development strategy beginning with autologous-derived cells before moving to a universal hypoimmunogenic cell line. Vita Therapeutics was founded in 2019 by Douglas Taylor Falk, M.S. and Peter Andersen, Ph.D. Douglas Taylor Falk has been the CEO since 2019. | Director/Board Member | - |
Our Lady of Mercy Academy | Director/Board Member | - |
Pyramid Biosciences, Inc.
Pyramid Biosciences, Inc. BiotechnologyHealth Technology Pyramid Biosciences, Inc. operates as a biotechnology company. It develops new therapies focused on the modulation of cell surface. The company was founded by Kollol Pal and Jordan Leef and is headquartered in Waltham, MA. | Director/Board Member | - |
Biohaven Pharmaceuticals, Inc.
Biohaven Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Biohaven Pharmaceuticals, Inc. engaged in the identification and development of clinical stage compounds targeting the glutamatergic system. The company in July 2013 and is headquartered in New Haven, CT. | Chief Executive Officer | - |
Veradermics, Inc.
Veradermics, Inc. Pharmaceuticals: MajorHealth Technology VeraDermics, Inc. is a clinical-stage biopharmaceutical company that focuses on developing drugs for immunologic and dermatologic diseases. The company is based in San Antonio, TX. The company has a portfolio of five product candidates that target common skin conditions such as warts, hair loss, and eczema. Founded by dermatologists, VeraDermics leverages its clinical experience to identify and advance novel drugs that address specific patient needs and solve pervasive treatment challenges in dermatology practice. | Director/Board Member | - |
Antiguos cargos conocidos de Vladimir Coric.
Empresas | Cargo | Fin |
---|---|---|
BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. | Chief Executive Officer | 03/10/2022 |
░░░░ ░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░░░░░░ ░░░░░░ ░░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░░░░ ░░░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░ | - |
Formación de Vladimir Coric.
Wake Forest School of Medicine | Doctorate Degree |
University of Connecticut | Undergraduate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas cotizadas | 3 |
---|---|
BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
REVANCE THERAPEUTICS, INC. | Health Technology |
BIOHAVEN LTD. | Health Technology |
Empresas privadas | 8 |
---|---|
Biohaven Pharmaceutical Holding Co. Ltd.
Biohaven Pharmaceutical Holding Co. Ltd. Pharmaceuticals: MajorHealth Technology Biohaven Pharmaceutical Holding Co. Ltd. is a clinical-stage biopharmaceutical company, which engages in the research and development of late-stage product candidates targeting neurological diseases, including rare disorders. It focuses on a pipeline of product candidates that represent mechanistic platforms, calcitonin gene-related peptide receptor antagonists, and glutamate modulators. The company was founded in September 2013 and is headquartered in New Haven, CT. | Health Technology |
Our Lady of Mercy Academy | |
Connecticut Psychiatric Society | |
Biohaven Pharmaceuticals, Inc.
Biohaven Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Biohaven Pharmaceuticals, Inc. engaged in the identification and development of clinical stage compounds targeting the glutamatergic system. The company in July 2013 and is headquartered in New Haven, CT. | Commercial Services |
Pyramid Biosciences, Inc.
Pyramid Biosciences, Inc. BiotechnologyHealth Technology Pyramid Biosciences, Inc. operates as a biotechnology company. It develops new therapies focused on the modulation of cell surface. The company was founded by Kollol Pal and Jordan Leef and is headquartered in Waltham, MA. | Health Technology |
Vita Therapeutics, Inc.
Vita Therapeutics, Inc. BiotechnologyHealth Technology Vita Therapeutics, Inc. is a biotechnology company based in Baltimore, MD that develops state-of-the-art cellular therapeutics for the treatment of neuromuscular diseases and cancers. The company uses induced pluripotent stem cell (iPSC) technology to engineer specific cell types designed to replace those that are defective in patients. Vita Therapeutics is progressing its co-leading programs VTA-100 and VTA-300 for the treatment of limb-girdle muscular dystrophy (LGMD) and multiple solid tumors with the goal of filing investigational drug applications with the Food and Drug Administration in 2023. The company is developing these proprietary cellular therapies following a dual development strategy beginning with autologous-derived cells before moving to a universal hypoimmunogenic cell line. Vita Therapeutics was founded in 2019 by Douglas Taylor Falk, M.S. and Peter Andersen, Ph.D. Douglas Taylor Falk has been the CEO since 2019. | Health Technology |
Veradermics, Inc.
Veradermics, Inc. Pharmaceuticals: MajorHealth Technology VeraDermics, Inc. is a clinical-stage biopharmaceutical company that focuses on developing drugs for immunologic and dermatologic diseases. The company is based in San Antonio, TX. The company has a portfolio of five product candidates that target common skin conditions such as warts, hair loss, and eczema. Founded by dermatologists, VeraDermics leverages its clinical experience to identify and advance novel drugs that address specific patient needs and solve pervasive treatment challenges in dermatology practice. | Health Technology |
Social Capital Suvretta Holdings Corp. I
Social Capital Suvretta Holdings Corp. I Financial ConglomeratesFinance Social Capital Suvretta Holdings Corp. I is a blank check company, which engages in effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. It focuses on the search for target business operating in the biotechnology industry and within the neurology subsector. The company was founded by Chamath Palihapitiya and Kishen C. Mehta on February 25, 2021 and is headquartered in Henderson, NV. | Finance |
- Bolsa de valores
- Insiders
- Vladimir Coric